Revenue and Profit Performance - Revenue for the third quarter was RMB 125.64 million, a decrease of 3.02% year-over-year[4] - Net profit attributable to shareholders was RMB -732,885.31, a significant decrease of 105.62% year-over-year[4] - Net profit attributable to the parent company decreased to 166.4 million yuan from 186.3 million yuan, a decline of 10.7%[14] - Net profit for the quarter was RMB 15.24 million, with a year-to-date net profit of RMB 45.93 million[16] - Total revenue for the period reached 391.4 million yuan, compared to 367.2 million yuan in the same period last year, representing a 6.6% increase[15] - Sales revenue from goods and services for the quarter was RMB 341.35 million, slightly down from RMB 352.72 million in the same period last year[17] Cash Flow and Financial Position - Operating cash flow for the first nine months was RMB 21.11 million, down 59.97% year-over-year[4] - Operating cash flow for the quarter was RMB 21.11 million, compared to RMB 52.72 million in the same period last year[17] - Investment cash flow improved by 83.63% to RMB -6.94 million, reflecting reduced payments for clinical new drug R&D projects[7] - Investment cash inflow for the quarter was RMB 597.25 million, a decrease from RMB 1 billion in the same period last year[17] - Total cash outflow from financing activities was RMB 130.64 million, with a net cash outflow of RMB 110.99 million[18] - Total cash outflow from investment activities was RMB 590.15 million, compared to RMB 1.66 billion in the same period last year[17] - The company's cash and cash equivalents decreased by RMB 79.99 million during the quarter[18] - Cash and cash equivalents at the end of the quarter were RMB 55.50 million, down from RMB 106.33 million at the end of the previous quarter[18] - Net cash flow from financing activities was -31,198,413.09, a decrease of 340.56% compared to the previous period, mainly due to cash dividends, share repurchases, and clinical new drug R&D expenses[8] Assets and Liabilities - Total assets decreased by 8.67% to RMB 1.36 billion compared to the end of the previous year[4] - Total assets decreased to 1.36 billion yuan from 1.49 billion yuan, a reduction of 8.8%[13] - Current assets declined to 620.5 million yuan from 731.3 million yuan, a 15.1% decrease[12] - Accounts receivable increased to 109.7 million yuan, up 28.3% from 85.5 million yuan in the previous period[12] - Inventory rose to 77.5 million yuan, a 26.1% increase compared to 61.4 million yuan in the prior year[12] - Short-term borrowings decreased to 12.3 million yuan from 15.9 million yuan, a 22.6% reduction[13] - Total liabilities decreased to 313.6 million yuan from 369.6 million yuan, a 15.1% decline[13] - Contract liabilities increased by 131.91% to RMB 5.15 million due to pre-receipts for uncompleted orders[7] - Deferred tax assets grew by 142.62% to RMB 24.97 million, driven by losses from clinical new drug R&D projects[7] R&D and Operating Costs - R&D expenses increased by 38.66% to RMB 13.08 million in the third quarter[7] - R&D expenses grew to 35.9 million yuan, a 25% increase compared to 28.7 million yuan in the prior year[15] - Operating costs increased to 396.6 million yuan, up from 319.4 million yuan in the previous year, reflecting a 24.2% rise[15] - Operating profit dropped by 131.95% to RMB -4.06 million, mainly due to incomplete capacity release in clinical new drug R&D projects[7] Shareholder and Equity Information - The total number of ordinary shareholders at the end of the reporting period was 12,390[8] - The largest shareholder, Hongbo Zhiyuan (Hong Kong) Pharmaceutical Technology Co., Ltd., holds 27.71% of the shares, totaling 38,675,000 shares[8] - Shenyang Fubang Investment Co., Ltd. holds 6.21% of the shares, totaling 8,663,200 shares[8] - Dingtai Haifu Investment Management Co., Ltd. holds 4.94% of the shares, totaling 6,901,230 shares[8] - Beijing Zhongfu Jishi Investment Center (Limited Partnership) holds 4.42% of the shares, totaling 6,164,860 shares[8] - Shanghai Dingyun Investment Management Consulting Partnership (Limited Partnership) holds 3.89% of the shares, totaling 5,423,600 shares[8] - Beijing Zhongfu Growth Equity Investment Center (Limited Partnership) holds 2.01% of the shares, totaling 2,802,800 shares[8] - The total number of restricted shares at the end of the period was 62,726,300, an increase of 14,475,300 shares compared to the beginning of the period[10] Earnings and Comprehensive Income - Basic earnings per share for the quarter were RMB 0.1099, with year-to-date basic earnings per share at RMB 0.4268[16] - Total comprehensive income for the quarter was RMB 15.24 million, with year-to-date comprehensive income at RMB 46.00 million[16] Financial Expenses - Financial expenses surged by 4409.66% to RMB 2.21 million due to unconfirmed financing fees for right-of-use assets[7]
泓博医药(301230) - 2024 Q3 - 季度财报